Lead Product(s): TLY012
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $5.9 million Upfront Cash: Undisclosed
Deal Type: Funding January 30, 2020
Theraly Fibrosis has been awarded a Small Business Innovation Research Phase II grant by the National Institutes of Health to support development of TLY012 for treatment of chronic pancreatitis.